4.8 Article

RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer

Journal

BIOMATERIALS
Volume 102, Issue -, Pages 231-238

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2016.06.024

Keywords

Drug delivery systems; Exosomes; Exosome-mimetics; Extracellular vesicles; siRNA delivery

Funding

  1. Swedish Research Council [K2014-85X-22504-01-3]
  2. VBG Group for Asthma and Allergy Research
  3. Swedish Heart and Lung Foundation [20120528]
  4. Swedish Cancer Foundation [CAN2012/690, CAN2014/844]
  5. National Research Foundation of Korea (NRF) - Korea government (MSIP) [2014-023004]
  6. International Research & Development Program - Ministry of Science, ICT and Future Planning of Korea [2013K2A3A1000115]
  7. Korea Health Technology R&D Project through Korea Health Industry Development Institute (KHIDI)
  8. Ministry of Health & Welfare, Republic of Korea [HI14C1277]

Ask authors/readers for more resources

To develop RNA-based therapeutics, it is crucial to create delivery vectors that transport the RNA molecule into the cell cytoplasm. Naturally released exosomes vesicles (also called Extracellular Vesicles) have been proposed as possible RNAi carriers, but their yield is relatively small in any cell culture system. We have previously generated exosome-mimetic nanovesicles (NV) by serial extrusions of cells through nano-sized filters, which results in 100-times higher yield of extracellular vesicles. We here test 1) whether NV can be loaded with siRNA exogenously and endogenously, 2) whether the siRNA-loaded NV are taken up by recipient cells, and 3) whether the siRNA can induce functional knock-down responses in recipient cells. A siRNA against GFP was first loaded into NV by electroporation, or a c-Myc shRNA was expressed inside of the cells. The NV were efficiently loaded with siRNA with both techniques, were taken up by recipient cells, which resulted in attenuation of target gene expression. In conclusion, our study suggests that exosome-mimetic nanovesicles can be a platform for RNAi delivery to cell cytoplasm. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available